Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases

SN Lin, R Mao, C Qian, D Bettenworth… - Physiological …, 2022 - journals.physiology.org
Intestinal fibrosis is considered an inevitable complication of Crohn's disease (CD) that
results in symptoms of obstruction and stricture formation. Endoscopic or surgical treatment …

Oral submucous fibrosis: a global challenge. Rising incidence, risk factors, management, and research priorities

JG Ray, R Chatterjee, K Chaudhuri - Periodontology 2000, 2019 - Wiley Online Library
Oral submucous fibrosis is a potentially malignant disorder of the oral cavity, with a high rate
of malignant transformation. It is very common among habitual areca nut chewers. The …

Drug treatment for oral submucous fibrosis: an update

X Chen, H Xie, J Guo - BMC oral health, 2023 - Springer
Objective The aim of this review is to evaluate the different medicinal interventions available
for the management of oral submucous fibrosis (OSF). Materials and methods We conducted …

Medicinal management of oral submucous fibrosis in the past decade-A systematic review

CB More, DJ Patil, NR Rao - Journal of oral biology and craniofacial …, 2020 - Elsevier
Introduction Oral submucous fibrosis (OSMF) is a potentially malignant disorder with a high
rate of malignant transformation. It is associated with chewing of areca nut and tobacco …

Comparative efficacy of interventions for the management of oral submucous fibrosis: a systematic review and network meta-analysis

D Gopinath, LM Hui, SK Veettil… - Journal of Personalized …, 2022 - mdpi.com
Introduction: Oral submucous fibrosis (OSMF) is a chronic premalignant condition and is
characterized by fibroblastic change of lamina propria and stiffness of oral mucosa. Though …

Repurposing pentoxifylline for the treatment of fibrosis: an overview

WX Wen, SY Lee, R Siang, RY Koh - Advances in Therapy, 2017 - Springer
Fibrosis is a potentially debilitating disease with high morbidity rates. It is estimated that half
of all deaths that occur in the USA are attributed to fibrotic disorders. Fibrotic disorders are …

Pentoxifylline–a review of its use in osteoradionecrosis

AJ Lyons, PA Brennan - British Journal of Oral and Maxillofacial Surgery, 2017 - Elsevier
Pentoxifylline has been used to treat complications related to fibrosis for over 20 years.
Formerly used to treat those after radiotherapy such as osteoradionecrosis (ORN), it is now …

Comparative analysis of two arecoline‐induced oral submucous fibrosis models

S Tang, L Jiang, Y Zhou, T Zhou, Y Peng… - Oral …, 2023 - Wiley Online Library
Objective The limited understanding of the molecular mechanism for oral submucosal
fibrosis (OSF) poses challenges to the development of effective prevention and treatment …

Comparison of triamcinolone with pentoxifylline and vitamin E efficacy in the treatment of stage 2 and 3 oral submucous fibrosis: A randomized clinical trial

SU Shah, S Nigar, R Yousofi, A Maqsood… - SAGE Open …, 2023 - journals.sagepub.com
Objective: The objective of this study was to assess the effectiveness of triamcinolone in
combination with pentoxifylline and vitamin E in the treatment of patients with level two and …

Evaluating the oral-health-related quality of life of oral submucous fibrosis patients before and after treatment using the OHIP-14 tool

AB Memon, AAU Rahman, KA Channar… - International Journal of …, 2022 - mdpi.com
The objective of the present study was to assess the oral-health-related quality of life
(OHRQoL) of oral submucous fibrosis (OSMF) patients before and after standard treatment …